BCL2L1 and systemic lupus erythematosus: Another Bcl-2 family protein inhibitor is ABT-737, which targets both Bcl-2 and Bcl-XL, thereby reducing disease activity in a CIA mouse model, and a significant protection of severe glomerulonephritis with prolonged survival in the animal model of SLE [33].